Skip to main content
SpringerLink
Log in

Inaccurate HER2 testing results in high economic societal loss

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2012 US dollars

Reference

  • Garrison LP Jr, et al. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health 18: 541-6, No. 4, Jun 2015

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inaccurate HER2 testing results in high economic societal loss. PharmacoEcon Outcomes News 731, 22 (2015). https://doi.org/10.1007/s40274-015-2251-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2251-2

Search

Navigation